ArticleJournal of experimental & clinical cancer research : CR2026
Prosaposin orchestrates a TGFβ1-driven paracrine loop between Schwann cells and gastric cancer to accelerate perineural invasion.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Perineural invasion (PNI) is an established adverse prognostic factor in gastric cancer (GC), yet the molecular events initiating this process remain poorly defined. In this study, we identify Schwann cells (SCs) as active facilitators of PNI and elucidate a reciprocal signaling axis between GC cells and SCs that promotes PNI. Using a GC–SCs co-culture model, we show that SCs enhance PNI potential in GC cells, accompanied by increased expression of prosaposin (PSAP), a lysosomal secretory protein, in both co-cultured cells and PNI-positive tumor specimens. Mechanistic studies reveal that PSAP forms a complex with cathepsin D (CTSD) and galactocerebrosidase (GALC) to inhibit autophagy and to promote PNI progression. GC-derived PSAP activates the G protein–coupled receptor 37(GPR37) on SCs, initiating RAC1-dependent cytoskeletal remodeling. This activation also induces secretion of transforming growth factor-β-1(TGFβ1) by SCs, which, in turn, binds transforming growth factor-β receptor-II (TGFβRII) on GC cells and activates a TGFβ1/Smad4/Sortilin signaling cascade. This pathway amplifies PSAP production and reinforces tumor–nerve interactions, establishing a feedforward paracrine loop that drives PNI. Functionally, enforced PSAP expression in GC cells significantly enhances PNI both in vitro and in vivo. Clinically, co-expression of PSAP, TGFβ1, and SCs marker S100β correlates with PNI incidence and improve PNI discrimination. Collectively, these findings define a novel PSAP–TGFβ1–Sortilin axis that mediates SCs–tumor crosstalk and sustains PNI in GC. Disrupting this paracrine loop may provide a therapeutic avenue to limit PNI and improve outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.